Tirzepatide
Tirzepatide is a synthetic peptide agonist of the GIP and GLP-1 receptors, studied across a large phase 3 clinical-trial programme. Atlas RND supplies it as a lyophilized research peptide for laboratory research use only.
Read the 14 published studiesLast updated
For laboratory research use only. The literature below is provided for educational reference by qualified researchers. It is not medical advice, and nothing on this page is a claim about Tirzepatide. Not for human or veterinary use.
Published research on Tirzepatide
Peer-reviewed studies grouped by what they investigated, with human clinical trials first, then reviews, then laboratory work. Each links to the original paper.
Obesity clinical trials 5 studies
Study title: Tirzepatide Once Weekly for the Treatment of Obesity.
Study title: Tirzepatide for Obesity Treatment and Diabetes Prevention.
Study title: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
Study title: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Study title: Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial.
Type 2 diabetes clinical trials 5 studies
Study title: Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
Study title: Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Study title: Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
Study title: Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.
Study title: Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Heart, liver and sleep apnea trials 3 studies
Study title: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
Study title: Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.
Study title: Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
Discovery and pharmacology 1 study
Study title: LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Important research notice. These studies are posted for research reference only. Titles are reproduced exactly as their authors published them and describe what those researchers investigated; they are not claims by Atlas RND about any product. Not for human consumption. All literature is provided for educational reference only and must not be interpreted as medical advice or product claims. Studies of a compound by other groups are not studies of Atlas RND material. By purchasing from Atlas RND you confirm you are a qualified researcher and will use products in accordance with all applicable laws and regulations. Back to the research library →
Molecular profile
Quality and lot testing
Related compounds
Retatrutide · NAD+ · Wolverine Stack · Glow · BPC-157 · TB-500 · GHK-Cu · DSIP · MOTS-C · Tirzepatide product page